MBF Therapeutics
Ambler, US · Delaware corporation
Biotech
Founders & leadership
TT
Thomas TillettExecutive
Board
CM
Christopher M. CashmanBoard director
Reported raises · per SEC filings
Form D private placements$2.6M disclosed across 4 rounds · 2016–2023
▶$105KraisedJan 2024 · 6 investors · BiotechnologyRule 506(b)
▶$105KraisedJan 2024 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dhiren ThakkerDirector
- Joseph ConnorDirector
- Aris PersidisDirector
- Lorraine KellerExecutive Officer
- Thomas TillettExecutive Officer, Director
- Christopher CashmanDirector
- Offering amount
- $500K
- Amount sold
- $105K
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$814.3KraisedSep 2021 · 21 investors · BiotechnologyRule 506(b)
▶$814.3KraisedSep 2021 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher M. CashmanDirector
- Aris PersidisDirector
- Dhiren ThakkerDirector
- Thomas TillettExecutive Officer, Director
- Chris BungeDirector
- Offering amount
- $3M
- Amount sold
- $814.3K
- Proceeds to insiders
- $75K
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$605KraisedMay 2019 · 16 investors · BiotechnologyRule 506(b)
▶$605KraisedMay 2019 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher M. CashmanDirector
- Thomas TillettExecutive Officer, Director
- Chris BungeDirector
- Offering amount
- $2M
- Amount sold
- $605K
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedNov 2016 · 14 investors · BiotechnologyRule 506(b)
▶$1.1MraisedNov 2016 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher M. CashmanDirector
- Thomas TillettExecutive Officer, Director
- Offering amount
- $1.1M
- Amount sold
- $1.1M
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapSouffletx3 shared keywordsSoufflé Therapeutics develops nucleic acid medicines that precisely target and deliver genetic therapeutics to specific cell types to treat disease. The company focuses on creating potent, precise medicines for patients across various disease areas through advanced delivery platforms.
Bambusa Therapeutics3 shared keywordsBambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications. The clinical-stage biotech company serves patients across a range of I&I diseases.
Companies competing with MBF Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase ISTTR | 2022 | $256K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- How much funding has MBF Therapeutics raised?
- MBF Therapeutics has disclosed $2.6M raised across 4 rounds.
- Where is MBF Therapeutics headquartered?
- MBF Therapeutics is headquartered in Ambler, US.